Protagenic Therapeutics Inc.

Protagenic Therapeutics Inc. is a biopharmaceutical company focused on developing novel peptide-based treatments. Its primary objective is to address central nervous system disorders, with an emphasis on conditions such as anxiety, depression, and PTSD. Protagenic Therapeutics utilizes its proprietary technology platform to explore and create therapeutic agents aimed at modulating neuropeptide systems, which play crucial roles in brain function and emotional regulation. The company's innovative approach targets unmet medical needs within the mental health sector, offering potential advancements in how these widespread conditions are managed. Operating in the highly specialized biotechnology industry, Protagenic Therapeutics contributes to the broader healthcare market by expanding treatment options and exploring new frontiers in neuroscience. Its work not only impacts the development of therapeutic initiatives but also enhances understanding of complex neurological disorders, positioning it as a key player in the ongoing evolution of mental health therapies. Based in New York, Protagenic Therapeutics is listed on the NASDAQ, reflecting its engagement with both scientific communities and the public markets.